LIVE
CRSP
CRISPR Therapeutics AG · Health Care - Gene Editing
$54.09
+13.66% this month
VERSUS
⟷
COMPARE
EDIT
Editas Medicine, Inc. · Health Care - Gene Editing
$2.69
+9.35% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
CRSP
3
EDIT
1
Comparison scoreboard
CRSP LEADS 3/5AI Score
CRSP ✓34.4
EDIT 24.5
1Y Return
CRSP ✓+21.74%
EDIT +14.47%
Fwd P/E
CRSP ✓-14.12
EDIT -2.87
Target Up.
CRSP +54.42%
EDIT ✓+114.79%
Op. Margin
CRSP N/A
EDIT N/A
Metrics last refreshed: 6/20/2026
Quick take
CRSP vs EDIT Stock Comparison: AI Score, Valuation, Performance and Upside
CRSP is the clear leader in the CRISPR gene editing space having achieved the first-ever CRISPR therapy approval (Casgevy) with Vertex Pharmaceuticals, while EDIT is an earlier-stage gene editing company with clinical programs still working toward proving its approach. Both face the broader challenges of gene therapy commercialization, but CRSP has a meaningful head start.
CRSP vs EDIT compares the leading CRISPR gene editing company with a commercially approved therapy against an earlier-stage CRISPR competitor still advancing programs through clinical development.
Live analysis · updated 6/20/2026
CRSP holds the edge across 3 of 5 key metrics in this comparison. CRSP leads on both 1-year return (+21.74%) and forward P/E (-14.12x vs -2.87x for EDIT), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for EDIT (+114.79%) than for CRSP (+54.42%).
Normalized 1Y performance
CRSP
EDIT
Recent returns
CRSP
EDIT
Analyst price targets & sentiment
CRSP · 21 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$44.00
analyst high$291.00
analyst mean$83.52
current price$54.09
+54.4% upside to analyst mean
EDIT · 9 analysts
Price target range
analyst low$1.00
analyst high$15.00
analyst mean$5.78
current price$2.69
+114.8% upside to analyst mean
Who should consider this stock?
CRSP may suit investors who:
- →Want exposure to the gene editing company that achieved the first CRISPR therapy approval
- →Value the Vertex partnership for financial backing and commercial infrastructure
- →Believe CRISPR-based cures will build into meaningful commercial franchises
EDIT may suit investors who:
- →Want earlier-stage exposure to in vivo CRISPR gene editing technology
- →See potential value in Editas's foundational IP and clinical programs at a smaller valuation
- →Are comfortable with higher clinical and execution risk in exchange for earlier-stage upside
Performance & AI score
| Metric | CRSP | EDIT |
|---|---|---|
| AI score | 34.4 | 24.5 |
| AI rank | #1740 | #3100 |
| Latest close | $54.09 | $2.69 |
| 1M return | +13.66% | +9.35% |
| 6M return | -1.19% | +13.50% |
| 1Y return | +21.74% | +14.47% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | CRSP | EDIT |
|---|---|---|
| 1Y ago | $12.17K (+21.7%) started 2025-06-18 | $11.45K (+14.5%) started 2025-06-18 |
| 5Y ago | $4.23K (-57.7%) started 2021-06-18 | $749.72 (-92.5%) started 2021-06-18 |
| 10Y ago | $38.39K (+283.9%) started 2016-10-19 | $906.33 (-90.9%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | CRSP | EDIT |
|---|---|---|
| Market cap | $5.33B | $412.81M |
| Trailing P/E | N/A | N/A |
| Forward P/E | -14.12 | -2.87 |
| Price/Sales | 1298.32 | 10.67 |
| EV/Revenue | 819.67 | 3.22 |
| Analyst target | $83.52 | $5.78 |
| Target upside | +54.42% | +114.79% |
Growth, profitability & risk
| Metric | CRSP | EDIT |
|---|---|---|
| Revenue growth | 68.60% | -39.20% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | -6358.66% | -190.77% |
| Operating margin | N/A | N/A |
| Profit margin | 0.00% | -281.59% |
| ROIC proxy | -31.21% | -326.07% |
| Return on equity | -31.21% | -326.07% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 1.70 | 2.10 |
| Debt/equity | 43.41 | 392.40 |
| Current ratio | 17.96 | 3.22 |
| Quick ratio | 17.92 | 3.17 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
CRSP max drawdown42.25%
EDIT max drawdown59.88%
CRSP max wkly drop17.63%
EDIT max wkly drop27.17%
5Y risk snapshot
CRSP max drawdown80.68%
EDIT max drawdown98.66%
CRSP max wkly drop21.49%
EDIT max wkly drop42.50%
10Y risk snapshot
CRSP max drawdown85.11%
EDIT max drawdown98.92%
CRSP max wkly drop30.47%
EDIT max wkly drop42.50%
Performance metrics by period
| Period | Metric | CRSP | EDIT |
|---|---|---|---|
| 1Y | Growth | +21.74% | +14.47% |
| CAGR | +21.76% | +14.48% | |
| Sharpe ratio | 0.55 | 0.55 | |
| Max drawdown | 42.25% | 59.88% | |
| Max daily drop | 11.59% | 15.57% | |
| Max wkly drop | 17.63% | 27.17% | |
| 5Y | Growth | -57.69% | -92.50% |
| CAGR | -15.80% | -40.44% | |
| Sharpe ratio | -0.06 | -0.16 | |
| Max drawdown | 80.68% | 98.66% | |
| Max daily drop | 13.32% | 35.63% | |
| Max wkly drop | 21.49% | 42.50% | |
| 10Y | Growth | +283.89% | -90.94% |
| CAGR | +14.94% | -21.36% | |
| Sharpe ratio | 0.46 | 0.06 | |
| Max drawdown | 85.11% | 98.92% | |
| Max daily drop | 17.10% | 35.63% | |
| Max wkly drop | 30.47% | 42.50% |
Business comparison
| Category | CRSP | EDIT |
|---|---|---|
| Company | CRISPR Therapeutics AG | Editas Medicine, Inc. |
| Sector | Health Care - Gene Editing | Health Care - Gene Editing |
| Industry | N/A | N/A |
| Core business | CRISPR Therapeutics uses CRISPR-Cas9 gene editing to develop transformative medicines, led by Casgevy (exa-cel), the first CRISPR-based therapy approved by the FDA — for sickle cell disease and beta-thalassemia — developed in partnership with Vertex Pharmaceuticals. | Editas Medicine is a clinical-stage gene editing company using CRISPR-Cas9 and other gene editing tools to develop medicines, with early programs in eye disease (Leber congenital amaurosis) and hematological conditions. |
| Investor focus | Investors track Casgevy's commercial launch and patient uptake, the next wave of in vivo CRISPR programs (particularly cardiovascular), and the overall expansion of the gene editing therapy pipeline. | Investors track Editas's clinical pipeline advancement, particularly its in vivo eye disease programs, and the company's strategic focus following earlier setbacks and pipeline restructuring. |
CRSP strengths
- →First company to achieve FDA approval for a CRISPR-based therapy (Casgevy for sickle cell disease and beta-thalassemia)
- →Partnership with Vertex Pharmaceuticals provides commercial infrastructure and significant financial backing
- →Strong cash position from Vertex partnership funding enables substantial R&D investment
EDIT strengths
- →Early-mover in CRISPR gene editing with foundational IP positions
- →In vivo gene editing approach (delivering CRISPR directly into the body) could be simpler to administer than ex vivo approaches if successful
- →Eye disease programs provide early clinical proof-of-concept opportunities
Risks to watch — CRSP
- →Casgevy's commercial uptake has been limited by complex manufacturing, treatment requirements (patient conditioning), and high price — adoption is slower than initially hoped
- →Ex vivo gene editing approach requires complex bone marrow transplantation-like procedures that limit eligible patient numbers
- →Competition from other gene therapies including Bluebird Bio's Lyfgenia
Risks to watch — EDIT
- →No commercially approved therapies yet; all programs are pre-commercial
- →Has faced clinical and operational setbacks that required pipeline restructuring
- →Significantly smaller than CRISPR Therapeutics in both resources and clinical advancement
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →